Hub : Traits :

Wheeze or whistling in the chest in last year

373 significantly associated models · 70 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	2	102118712	103686111	5	1	4.3e-31	1.3e-24	3.6e-02	96	IL1RL1
2	2	160551143	161166234	1	1	1.4e-07	3.1e-05	2.4e-02	71	PLA2R1
3	2	241941773	243048760	6	2	1.4e-12	5.5e-14	6.9e-01	100	AC114730.7 D2HGDH
4	3	48606701	50921261	15	1	2.0e-13	7.2e-13	1.0e+00	100	RBM6
5	4	122842267	123530993	1	1	5.5e-08	4.1e-07	1.4e-02	76	KIAA1109
6	5	109716442	111105293	1	1	1.7e-08	1.2e-15	7.1e-14	13	TSLP
7	9	4934896	7345304	2	2	2.6e-11	3.8e-29	1.2e-14	52	GLDC KIAA1432
8	9	138920796	140321666	1	1	7.9e-10	2.4e-09	1.0e+00	100	SNHG7
9	11	75678647	77069746	1	1	9.6e-08	2.0e-12	2.0e-06	54	LRRC32
10	11	110776537	112491227	5	1	9.6e-09	1.0e-08	1.0e+00	100	FDXACB1
11	12	66068136	67896003	1	1	2.0e-07	8.4e-06	7.9e-04	43	GRIP1
12	13	99155113	100728229	1	1	1.7e-08	2.5e-07	8.7e-02	89	UBAC2
13	15	66662107	68183665	1	1	1.4e-13	8.8e-15	8.6e-03	88	SMAD3
14	16	10329905	12010444	5	1	3.3e-13	1.8e-18	8.8e-07	69	DEXI
15	16	29972690	31370090	1	1	8.9e-08	2.8e-06	7.7e-01	100	FBRS
16	17	36710513	39048774	16	1	1.9e-14	2.6e-13	5.7e-02	93	RAPGEFL1
17	20	61576647	62912463	7	1	6.3e-10	7.3e-10	1.0e+00	100	ARFRP1

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Respiratory disease	38.75	15	13	28.9	0.96	7.4e-09	AC114730.7 ARFRP1 D2HGDH DEXI FDXACB1 GLDC IL1RL1 KIAA1109 KIAA1432 LRRC32 RAPGEFL1 RBM6 SMAD3 TSLP UBAC2
Asthma	37.91	15	12	26.7	0.96	7.1e-09	AC114730.7 ARFRP1 D2HGDH DEXI FDXACB1 GLDC IL1RL1 KIAA1109 KIAA1432 LRRC32 RAPGEFL1 RBM6 SMAD3 TSLP UBAC2
Allergy	37.71	14	13	28.9	-0.97	1.3e-08	AC114730.7 ARFRP1 D2HGDH DEXI FDXACB1 GLDC IL1RL1 KIAA1109 KIAA1432 LRRC32 RAPGEFL1 SMAD3 TSLP UBAC2
Asthma (self-reported)	37.61	15	12	26.7	0.96	9.8e-09	AC114730.7 ARFRP1 D2HGDH DEXI FDXACB1 GLDC IL1RL1 KIAA1109 KIAA1432 LRRC32 RAPGEFL1 RBM6 SMAD3 TSLP UBAC2
Allergy or Eczema	31.26	13	11	24.4	0.95	7.0e-07	AC114730.7 ARFRP1 D2HGDH DEXI FDXACB1 GLDC IL1RL1 KIAA1109 KIAA1432 LRRC32 RAPGEFL1 SMAD3 TSLP
Blood Eosinophil Count	29.43	14	12	26.7	0.89	2.5e-05	AC114730.7 D2HGDH DEXI FBRS GLDC IL1RL1 KIAA1109 KIAA1432 LRRC32 PLA2R1 RBM6 SMAD3 TSLP UBAC2
Hayfever, allergic rhinitis or eczema	27.69	13	10	22.2	0.95	1.1e-06	AC114730.7 ARFRP1 D2HGDH DEXI FDXACB1 GLDC IL1RL1 KIAA1109 KIAA1432 LRRC32 RAPGEFL1 SMAD3 TSLP
Hayfever/allergic rhinitis (self-reported)	17.22	11	8	17.8	0.98	2.7e-07	AC114730.7 D2HGDH DEXI GLDC IL1RL1 KIAA1109 KIAA1432 LRRC32 RAPGEFL1 SMAD3 TSLP
Medication: Ventolin 100micrograms inhaler	16.50	9	6	13.3	1.00	4.7e-09	AC114730.7 D2HGDH GLDC IL1RL1 KIAA1109 KIAA1432 LRRC32 RAPGEFL1 SMAD3
Blood White Count	13.56	7	5	11.1	0.53	2.2e-01	ARFRP1 DEXI FBRS IL1RL1 PLA2R1 RAPGEFL1 RBM6
Irritable Bowel Disease (IBD)	8.91	6	6	13.3	0.43	4.0e-01	ARFRP1 KIAA1109 LRRC32 RAPGEFL1 RBM6 SMAD3
Medication: Seretide 50 evohaler	8.91	4	1	2.2	0.99	1.0e-02	AC114730.7 D2HGDH IL1RL1 SMAD3
Crohns Disease (2017)	7.04	6	4	8.9	0.50	3.2e-01	ARFRP1 KIAA1109 LRRC32 RAPGEFL1 RBM6 SMAD3
Crohns Disease (2012)	6.92	5	3	6.7	0.48	4.2e-01	ARFRP1 LRRC32 RAPGEFL1 RBM6 SMAD3
Ulcerative Colitis	6.84	4	3	6.7	0.21	7.9e-01	ARFRP1 KIAA1109 RAPGEFL1 RBM6
Taking other prescription medications	6.81	4	2	4.4	0.93	6.8e-02	D2HGDH IL1RL1 RAPGEFL1 RBM6
Ulcerative Colitis (UC)	6.55	6	4	8.9	0.29	5.7e-01	ARFRP1 KIAA1109 LRRC32 RAPGEFL1 RBM6 SMAD3
Number of self-reported non-cancer illnesses	6.28	5	0	0.0	0.98	2.8e-03	ARFRP1 D2HGDH IL1RL1 LRRC32 RAPGEFL1
Forced expiratory volume in 1-second (FEV1), predicted percentage	4.20	4	2	4.4	-0.96	3.5e-02	ARFRP1 FBRS PLA2R1 RAPGEFL1
Leg fat mass (left)	4.02	4	3	6.7	1.00	6.9e-04	ARFRP1 FBRS PLA2R1 RBM6
Body mass index (BMI)	3.99	2	2	4.4	0.00	1.0e+00	FBRS RBM6
Leg fat mass (right)	3.97	4	3	6.7	1.00	5.1e-04	ARFRP1 FBRS PLA2R1 RBM6
Leg fat percentage (left)	3.91	4	3	6.7	1.00	2.0e-03	ARFRP1 FBRS PLA2R1 RBM6
Chest pain or discomfort	3.88	3	0	0.0	0.00	1.0e+00	IL1RL1 RAPGEFL1 RBM6
Leg fat percentage (right)	3.78	4	3	6.7	1.00	9.8e-04	ARFRP1 FBRS PLA2R1 RBM6
Number of treatments/medications taken	3.73	1	1	2.2	0.00	1.0e+00	RBM6
Emphysema/chronic bronchitis	3.72	1	0	0.0	0.00	1.0e+00	RAPGEFL1
Arm fat mass (left)	3.62	3	2	4.4	0.00	1.0e+00	ARFRP1 FBRS RBM6
Arm fat mass (right)	3.58	3	2	4.4	0.00	1.0e+00	ARFRP1 FBRS RBM6
Whole body fat mass	3.58	4	3	6.7	1.00	2.9e-04	ARFRP1 FBRS PLA2R1 RBM6
Qualifications: College or University degree	3.51	3	1	2.2	0.00	1.0e+00	ARFRP1 FBRS RBM6
Primary Biliary Cirrhosis	3.45	1	1	2.2	0.00	1.0e+00	RAPGEFL1
Waist circumference	3.45	4	2	4.4	0.99	7.0e-03	ARFRP1 FBRS PLA2R1 RBM6
BMI	3.43	4	2	4.4	1.00	2.4e-03	ARFRP1 FBRS PLA2R1 RBM6
Body fat percentage	3.26	4	3	6.7	1.00	1.2e-03	ARFRP1 FBRS PLA2R1 RBM6
Lung FEV1/FVC ratio	3.19	8	3	6.7	-1.00	1.3e-07	AC114730.7 D2HGDH DEXI GLDC IL1RL1 KIAA1432 RAPGEFL1 SMAD3
Chronic bronchitis/emphysema (mother)	3.17	1	0	0.0	0.00	1.0e+00	RBM6
Hip circumference	3.10	3	3	6.7	0.00	1.0e+00	ARFRP1 FBRS RBM6
Arm fat percentage (right)	3.09	3	2	4.4	0.00	1.0e+00	ARFRP1 FBRS RBM6
Age at first live birth	3.09	1	1	2.2	0.00	1.0e+00	RBM6
Arm fat percentage (left)	3.07	3	2	4.4	0.00	1.0e+00	ARFRP1 FBRS RBM6
Trunk fat mass	3.03	4	3	6.7	1.00	9.6e-04	ARFRP1 FBRS PLA2R1 RBM6
Weight	3.02	4	2	4.4	1.00	6.3e-04	ARFRP1 FBRS GRIP1 RBM6
Overall health rating	2.94	2	2	4.4	0.00	1.0e+00	FBRS RBM6
Shortness of breath walking on level ground	2.93	1	0	0.0	0.00	1.0e+00	LRRC32
Age at last live birth	2.90	1	1	2.2	0.00	1.0e+00	RBM6
Age at First Birth	2.80	1	1	2.2	0.00	1.0e+00	RBM6
Trunk fat percentage	2.79	4	3	6.7	1.00	2.7e-03	ARFRP1 FBRS PLA2R1 RBM6
Medication: Co-codamol	2.76	1	0	0.0	0.00	1.0e+00	RBM6
Qualifications: A levels/AS levels or equivalent	2.75	1	1	2.2	0.00	1.0e+00	RBM6
HDL Cholesterol	2.72	1	1	2.2	0.00	1.0e+00	RAPGEFL1
Prostate Cancer	2.71	1	1	2.2	0.00	1.0e+00	ARFRP1
Impedance of arm (right)	2.58	4	3	6.7	0.17	8.3e-01	FBRS LRRC32 RAPGEFL1 RBM6
Lung FVC	2.56	3	1	2.2	0.00	1.0e+00	ARFRP1 FBRS RBM6
Knee pain experienced in last month	2.56	2	0	0.0	0.00	1.0e+00	FBRS RBM6
Current tobacco smoking	2.52	1	0	0.0	0.00	1.0e+00	ARFRP1
Coronary Artery Disease (CAD)	2.50	1	0	0.0	0.00	1.0e+00	RBM6
Impedance of arm (left)	2.46	4	2	4.4	0.14	8.6e-01	FBRS LRRC32 RAPGEFL1 RBM6
Arm predicted mass (left)	2.30	3	2	4.4	0.00	1.0e+00	FBRS GRIP1 RBM6
Intelligence (Savage-Jansen 2018)	2.29	1	1	2.2	0.00	1.0e+00	RBM6
Miserableness	2.29	2	1	2.2	0.00	1.0e+00	RAPGEFL1 RBM6
Arm fat-free mass (left)	2.27	3	2	4.4	0.00	1.0e+00	FBRS GRIP1 RBM6
Smoking status: Current	2.23	1	0	0.0	0.00	1.0e+00	ARFRP1
Pain experienced in last month	2.23	2	0	0.0	0.00	1.0e+00	FBRS RBM6
Schizophrenia vs Biploar Disorder	2.22	1	0	0.0	0.00	1.0e+00	RBM6
Fluid intelligence score	2.22	1	1	2.2	0.00	1.0e+00	RBM6
Forced expiratory volume in 1-second (FEV1), Best measure	2.22	4	1	2.2	-0.98	1.5e-02	ARFRP1 FBRS PLA2R1 RBM6
Arm predicted mass (right)	2.22	4	2	4.4	0.60	4.0e-01	FBRS GRIP1 RBM6 SNHG7
Mouth/teeth dental problems: Dentures	2.19	1	1	2.2	0.00	1.0e+00	RBM6
Arm fat-free mass (right)	2.11	2	2	4.4	0.00	1.0e+00	FBRS RBM6
Alcohol intake versus 10 years previously	2.10	1	1	2.2	0.00	1.0e+00	RBM6
Ever highly irritable/argumentative for 2 days	2.09	1	1	2.2	0.00	1.0e+00	RBM6
Impedance of whole body	2.06	3	2	4.4	0.00	1.0e+00	FBRS LRRC32 RBM6
Cardiovascular Disease	2.01	2	2	4.4	0.00	1.0e+00	FBRS FDXACB1
Birth weight	1.96	2	1	2.2	0.00	1.0e+00	FDXACB1 PLA2R1
Diastolic blood pressure, automated reading	1.94	3	0	0.0	0.00	1.0e+00	ARFRP1 FBRS RBM6
Verbal and Numeric Reasoning (VNR)	1.93	1	1	2.2	0.00	1.0e+00	RBM6
Basal metabolic rate	1.93	2	2	4.4	0.00	1.0e+00	FBRS RBM6
Forced expiratory volume in 1-second (FEV1)	1.92	2	1	2.2	0.00	1.0e+00	ARFRP1 RBM6
Type 2 Diabetes (T2D) (2018)	1.90	1	0	0.0	0.00	1.0e+00	RBM6
Financial difficulties in last 2 years	1.89	1	0	0.0	0.00	1.0e+00	FBRS
Medication: Blood pressure	1.87	2	0	0.0	0.00	1.0e+00	FBRS FDXACB1
Leg pain on walking	1.86	1	0	0.0	0.00	1.0e+00	RBM6
Number of operations (self-reported)	1.85	2	0	0.0	0.00	1.0e+00	DEXI RBM6
Mouth/teeth dental problems: Mouth ulcers	1.84	1	0	0.0	0.00	1.0e+00	RAPGEFL1
Alzheimer’s Disease (in mother)	1.82	1	0	0.0	0.00	1.0e+00	FBRS
Forced vital capacity (FVC), Best measure	1.81	3	1	2.2	0.00	1.0e+00	ARFRP1 FBRS RBM6
Alcohol intake frequency.	1.80	2	2	4.4	0.00	1.0e+00	FBRS RBM6
Exposure to tobacco smoke outside home	1.79	1	0	0.0	0.00	1.0e+00	RBM6
Diabetes diagnosed by doctor	1.79	1	0	0.0	0.00	1.0e+00	RBM6
Leg fat-free mass (left)	1.78	2	2	4.4	0.00	1.0e+00	FBRS RBM6
Leg predicted mass (left)	1.78	2	2	4.4	0.00	1.0e+00	FBRS RBM6
Forced vital capacity (FVC)	1.78	1	1	2.2	0.00	1.0e+00	ARFRP1
Smoking Status	1.77	1	0	0.0	0.00	1.0e+00	ARFRP1
Frequency of tenseness / restlessness in last 2 weeks	1.76	1	0	0.0	0.00	1.0e+00	RBM6
Qualifications: NVQ or HND or HNC or equivalent	1.76	1	0	0.0	0.00	1.0e+00	RBM6
Qualifications: None of the above	1.73	1	1	2.2	0.00	1.0e+00	RBM6
Average weekly beer plus cider intake	1.73	1	1	2.2	0.00	1.0e+00	RBM6
Alzheimer’s Disease (including proxy)	1.70	1	0	0.0	0.00	1.0e+00	FBRS
Heart disease (siblings)	1.69	1	0	0.0	0.00	1.0e+00	SMAD3
Vascular/heart problems diagnosed by doctor	1.68	2	1	2.2	0.00	1.0e+00	FBRS FDXACB1
Number of incorrect matches in round	1.66	1	1	2.2	0.00	1.0e+00	FBRS
Medication for cholesterol, blood pressure or diabetes	1.64	1	0	0.0	0.00	1.0e+00	FDXACB1
Leg fat-free mass (right)	1.62	2	2	4.4	0.00	1.0e+00	FBRS RBM6
Whole body water mass	1.60	3	2	4.4	0.00	1.0e+00	FBRS RBM6 SNHG7
Leg predicted mass (right)	1.60	2	2	4.4	0.00	1.0e+00	FBRS RBM6
Diabetes (self-reported)	1.58	1	0	0.0	0.00	1.0e+00	RBM6
Whole body fat-free mass	1.57	3	2	4.4	0.00	1.0e+00	FBRS RBM6 SNHG7
High blood pressure	1.53	2	1	2.2	0.00	1.0e+00	FBRS FDXACB1
Hypertension (Self-reported)	1.53	2	1	2.2	0.00	1.0e+00	FBRS FDXACB1
Impedance of leg (right)	1.52	2	2	4.4	0.00	1.0e+00	FBRS RBM6
Impedance of leg (left)	1.51	2	2	4.4	0.00	1.0e+00	FBRS RBM6
Triglycerides	1.47	1	0	0.0	0.00	1.0e+00	FBRS
Illnesses of siblings	1.47	1	0	0.0	0.00	1.0e+00	FBRS
Mood swings	1.39	1	1	2.2	0.00	1.0e+00	RBM6
Past tobacco smoking	1.38	1	0	0.0	0.00	1.0e+00	GLDC
Chronotype (morning person)	1.35	1	0	0.0	0.00	1.0e+00	KIAA1109
Tense / 'highly strung'	1.34	1	0	0.0	0.00	1.0e+00	FBRS
Depressed Affect (Nagel 2018)	1.33	1	1	2.2	0.00	1.0e+00	RBM6
Cholesterol lowering medication	1.31	1	0	0.0	0.00	1.0e+00	FBRS
Medication: Blood pressure	1.30	1	0	0.0	0.00	1.0e+00	FDXACB1
Fed-up feelings	1.29	1	1	2.2	0.00	1.0e+00	RBM6
Hypothyroidism/myxoedema (self-reported)	1.28	1	0	0.0	0.00	1.0e+00	KIAA1109
Trunk fat-free mass	1.27	3	2	4.4	0.00	1.0e+00	FBRS RBM6 SNHG7
Trunk predicted mass	1.27	3	2	4.4	0.00	1.0e+00	FBRS RBM6 SNHG7
Age when periods started (menarche)	1.24	1	0	0.0	0.00	1.0e+00	RBM6
High blood pressure (siblings)	1.24	1	0	0.0	0.00	1.0e+00	FBRS
Pulse rate, automated reading	1.21	2	0	0.0	0.00	1.0e+00	FDXACB1 RBM6
Hypothyroidism (self reported)	1.18	1	0	0.0	0.00	1.0e+00	KIAA1109
Heel T-Score	1.17	3	2	4.4	0.00	1.0e+00	FBRS RBM6 SNHG7
Comparative body size at age 10	1.12	1	0	0.0	0.00	1.0e+00	FBRS
Waist Hip Ratio (WHR)	1.06	2	0	0.0	0.00	1.0e+00	DEXI SMAD3
Systolic Blood Pressure	1.02	1	1	2.2	0.00	1.0e+00	FDXACB1
Heel bone mineral density (BMD) T-score, automated (left)	1.02	1	0	0.0	0.00	1.0e+00	RBM6
Qualifications: nursing, teaching	1.02	1	0	0.0	0.00	1.0e+00	RBM6
Hand grip strength (left)	0.94	1	0	0.0	0.00	1.0e+00	FBRS
Neuroticism score	0.87	1	0	0.0	0.00	1.0e+00	RBM6
Qualifications: O levels/GCSEs or equivalent	0.84	1	0	0.0	0.00	1.0e+00	RBM6
Blood Red Count	0.81	2	2	4.4	0.00	1.0e+00	ARFRP1 FBRS
Blood Platelet Count	0.72	2	1	2.2	0.00	1.0e+00	ARFRP1 PLA2R1
Sitting height	0.70	2	1	2.2	0.00	1.0e+00	FDXACB1 SNHG7
Height	0.68	4	2	4.4	-0.98	1.8e-02	ARFRP1 FDXACB1 GRIP1 SNHG7
Standing height	0.47	1	1	2.2	0.00	1.0e+00	SNHG7
Hair Pigment	0.15	1	1	2.2	0.00	1.0e+00	KIAA1432

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Brain Frontal Cortex BA9	4	0.433	2.0
GTEx	Adipose Visceral Omentum	4	0.196	1.9
GTEx	Artery Aorta	4	0.134	1.9
GTEx	Artery Tibial	8	0.213	1.9
GTEx	Brain Cerebellar Hemisphere	5	0.336	1.9
GTEx	Brain Cerebellum	6	0.303	1.9
GTEx	Brain Cortex	3	0.290	1.9
GTEx	Brain Putamen basal ganglia	3	0.481	1.9
GTEx	Breast Mammary Tissue	8	0.405	1.9
GTEx	Breast Mammary Tissue (Female)	4	0.243	1.9
GTEx	Cells Transformed fibroblasts	12	0.286	1.9
GTEx	Colon Sigmoid	2	0.137	1.9
GTEx	Colon Transverse	8	0.388	1.9
GTEx	Esophagus Muscularis	6	0.186	1.9
GTEx	Prostate	2	0.240	1.9
GTEx	Skin Not Sun Exposed Suprapubic	7	0.285	1.9
GTEx	Skin Sun Exposed Lower leg	9	0.247	1.9
GTEx	Small Intestine Terminal Ileum	1	0.217	1.9
GTEx	Spleen	8	0.567	1.9
GTEx	Thyroid	13	0.325	1.9
GTEx	Uterus	2	0.353	1.9
The Cancer Genome Atlas	Stomach Adenocarcinoma	6	0.356	1.9
GTEx	Adipose Subcutaneous	5	0.143	1.8
GTEx	Artery Coronary	1	0.085	1.8
GTEx	Brain Hypothalamus	1	0.169	1.8
GTEx	Brain Nucleus accumbens basal ganglia	3	0.347	1.8
GTEx	Breast Mammary Tissue (Male)	3	0.251	1.8
GTEx	Cells EBV-transformed lymphocytes	2	0.141	1.8
GTEx	Esophagus Gastroesophageal Junction	3	0.208	1.8
GTEx	Esophagus Mucosa	9	0.271	1.8
GTEx	Heart Atrial Appendage	4	0.253	1.8
GTEx	Heart Left Ventricle	2	0.131	1.8
GTEx	Lung	5	0.174	1.8
GTEx	Nerve Tibial	5	0.116	1.8
GTEx	Ovary	1	0.110	1.8
GTEx	Pancreas	4	0.245	1.8
GTEx	Pituitary	3	0.269	1.8
GTEx	Stomach	3	0.206	1.8
GTEx	Testis	9	0.285	1.8
GTEx	Whole Blood	7	0.351	1.8
NTR	Blood	5	0.208	1.8
ROSMAP	Brain Pre-frontal Cortex	8	0.182	1.8
YFS	Blood	7	0.152	1.8
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	4	0.242	1.8
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	6	0.220	1.8
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	13	0.317	1.8
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	4	0.195	1.8
The Cancer Genome Atlas	Lung Adenocarcinoma	8	0.272	1.8
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	7	0.279	1.8
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	7	0.421	1.8
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.187	1.8
The Cancer Genome Atlas	Testicular Germ Cell Tumors	4	0.313	1.8
The Cancer Genome Atlas	Thyroid Carcinoma	11	0.213	1.8
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	1	0.197	1.8
GTEx	Adrenal Gland	3	0.206	1.7
GTEx	Brain Caudate basal ganglia	2	0.217	1.7
GTEx	Muscle Skeletal	7	0.242	1.7
GTEx	Vagina	1	0.157	1.7
METSIM	Adipose	7	0.152	1.7
CommonMind	Brain Pre-frontal Cortex	12	0.223	1.7
The Cancer Genome Atlas	Breast Invasive Carcinoma	12	0.272	1.7
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	3	0.273	1.7
The Cancer Genome Atlas	Colon Adenocarcinoma	6	0.291	1.7
The Cancer Genome Atlas	Esophageal Carcinoma	1	0.146	1.7
The Cancer Genome Atlas	Glioblastoma Multiforme	2	0.196	1.7
The Cancer Genome Atlas	Brain Lower Grade Glioma	10	0.232	1.7
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	3	0.271	1.7
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	3	0.188	1.7
The Cancer Genome Atlas	Prostate Adenocarcinoma	12	0.260	1.7
GTEx	Brain Hippocampus	0	0.000	1.6
GTEx	Liver	2	0.279	1.6
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	3	0.226	1.6
The Cancer Genome Atlas	Rectum Adenocarcinoma	2	0.289	1.6
The Cancer Genome Atlas	Soft Tissue Sarcoma	1	0.094	1.6